2,2-dibromo-1-(4-(dimethylamino)phenyl)ethanone | 210832-81-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-dibromo-1-(4-(dimethylamino)phenyl)ethanone
• 英文别名: 2,2-dibromo-1-[4-(dimethylamino)phenyl]ethanone
• CAS: 210832-81-8
• 化学式: C₁₀H₁₁Br₂NO
• 分子量: 321.011
• InChiKey: DONBGMGUENRFLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-dibromo-1-(4-(dimethylamino)phenyl)ethanone 在 三乙胺 、 diethyl phosphite 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 12.0h， 生成 7-bromo-2-(4-dimethylaminophenyl)-imidazo[2,1-b]benzothiazole
  参考文献：
  名称：

  2-Arylimidazo[2,1-b]benzothiazoles: A new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer’s brain

  摘要：

  We designed and synthesized a small series of 2-aryl-imidazo[2,1-b]benzothiazole, representing a combination of motifs from the two most potent amyloid imaging agents, PIB and IMPY. The binding affinity of the new compounds ranged from 6 to 133 nM. Among the best compounds, 3b (K-i = 6 nM) can be labeled with (CH3)-C-11 for PET imaging whereas 3j (K-i = 10.9 nM) can be labeled with I-123 for SPECT imaging. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.052
• 作为产物：
  描述：

  二甲氨基苯乙酮 在 硫酸 、 溴 作用下， 以87%的产率得到2,2-dibromo-1-(4-(dimethylamino)phenyl)ethanone
  参考文献：
  名称：

  Radiosynthesis of SPECT tracers via a copper mediated ¹²³I iodination of (hetero)aryl boron reagents

  摘要：

  芳基硼酸皮纳科酯和酸的Cu介导的[¹²³I]碘化反应具有广泛的适用范围，并成功应用于四种放射示踪剂的标记，[¹²³I]DPA-713，[¹²³I]IMPY，[¹²³I]MIBG和[¹²³I]IPEB。

  DOI：

  10.1039/c6cc07417k

文献信息

• RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND
  申请人：Nihon Medi-Physics Co., Ltd.

  公开号：US20140088306A1

  公开（公告）日：2014-03-27

  Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound.

  提供了一种作为靶向淀粉样蛋白的诊断成像探针的复合物，以及包括该复合物的阿尔茨海默病诊断药剂。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：RODIN THERAPEUTICS INC

  公开号：WO2015200619A1

  公开（公告）日：2015-12-30

  This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

  这项发明提供了抑制HDAC2的化合物。这些化合物（例如，符合式（I）、（II）、（IIa）、（III）、（IV）、（V）或（VI）的化合物）可用于治疗、缓解或预防受试者的疾病，如神经系统疾病、记忆或认知功能障碍或损伤、消退学习障碍、真菌疾病或感染、炎症性疾病、血液疾病或肿瘤性疾病，或用于改善记忆或治疗、缓解或预防记忆丧失或损伤。
• Efficient and simple preparation of functionalized 1,1-dibromoenol phosphates
  作者：Vladislav Kotek、Peter Polák、Tomáš Tobrman

  DOI：10.1007/s00706-015-1613-6

  日期：2016.2

  AbstractThe preparation of functionalized 1,1-dibromoalkenyl phosphates is described. The protocol developed for their preparation is based on the generation of enolates from α,α-dibromoketones followed by a reaction with dialkyl chlorophosphates. The procedure tolerates various functional groups including ester, ketone, and nitrile, and the yields are generally high. Graphical abstract

  摘要描述了官能化的1，1-二溴烯基磷酸酯的制备。为制备它们而开发的方案是基于从α，α-二溴酮生成烯醇盐，然后与氯代磷酸二烷基酯反应。该方法耐受各种官能团，包括酯，酮和腈，并且产率通常很高。 图形概要
• Intramolecular sensitisation of lanthanide(iii) luminescence by acetophenone-containing ligands: the critical effect of para-substituents and solvent
  作者：Andrew Beeby、Lisa M. Bushby、Davide Maffeo、J. A. Gareth Williams

  DOI：10.1039/b105966c

  日期：2002.12.17

  Tetraazamacrocyclic ligands have been prepared in which three of the four nitrogen atoms are functionalised with carboxylate donors and the fourth is alkylated with a para-substituted acetophenone group –CH2C(O)C6H4–X, where X = H, OMe, NMe2}. The europium(III), gadolinium(III) and (for X = H) terbium(III) complexes of these potentially octadentate ligands have been prepared. The unsubstituted and methoxy-substituted ligands sensitise the europium(III) emissive state with high efficiency in aqueous solution. Calculation of the pure radiative lifetime, based on the contribution of the 5D0 → 7F1 transition to the total integrated emission intensity, has allowed an estimate of the efficiency of energy transfer to be made. Sensitisation of europium luminescence also occurs in the complex of the dimethylamino-substituted ligand but the process is highly solvent-dependent: very efficient sensitisation is observed in dichloromethane and DMSO, but the complex is non-emissive in water and only slightly emissive in acetonitrile. UV-Visible absorption spectra indicate that in all the solvents investigated, the carbonyl oxygen of the ligand is directly coordinated to the metal ion. The intensity of the hypersensitive 5D0 → 7F2 transition in the three complexes mirrors the degree of polarisation of the ketone CO bond.

  四氮大环配体已经制备，其中四个氮原子中的三个被羧酸盐供体功能化，第四个则与对取代的乙酰苯酮基团（–CH2C(O)C6H4–X，其中X=H，OMe，NMe2）烷基化。这些潜在的八齿配体的铕(III)、镓(III)和（对于X=H）铽(III)复合物已被制备。未取代和甲氧基取代的配体在水溶液中以高效能激发铕(III)的发射态。基于5D0 → 7F1跃迁对总积分发射强度的贡献，计算了纯辐射寿命，从而能够估算能量传递的效率。在二甲基氨基取代配体的复合物中也观察到了铕荧光的敏化，但这一过程高度依赖溶剂：在二氯甲烷和DMSO中观察到了非常高效的敏化，但该复合物在水中不发光，在乙腈中仅稍微发光。UV-可见吸收光谱表明，在所有研究的溶剂中，配体的羰基氧直接与金属离子配位。这三种复合物中，超敏感的5D0 → 7F2跃迁的强度反映了酮CO键的极化程度。
• Compounds and amyloid probes thereof for therapeutic and imaging uses
  申请人：Tamagnan D. Gilles

  公开号：US20070258887A1

  公开（公告）日：2007-11-08

  The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.

  本发明提供了化合物及其淀粉样探针，使得可以通过体内成像诊断AD并定量评估脑部区域中淀粉沉积（斑块）的程度或进展的方法。优选地，本发明的淀粉样探针可以穿过血脑屏障，并区分AD脑与正常脑。可以将淀粉样探针以适量用于体内成像淀粉沉积的方式给患者。本发明的淀粉样探针还可用于检测和定量包括但不限于唐氏综合症、家族性AD和载脂蛋白E4等位基因纯合子在内的疾病中的淀粉沉积。在一个方面，这些化合物可用于治疗或预防包括但不限于AD和2型糖尿病的疾病。该发明的化合物和淀粉样探针包括其类似物、盐、药物组合物、衍生物、前药、外消旋混合物或互变异构体。